With FDA approval, Supernus’ Qelbree is the first nonstimulant ADHD med for adults in 2 decadesnews2022-05-02T16:34:37+00:00May 2nd, 2022|Fierce Pharma|
Emergent mourns passing of founder and former CEO El-Hibri just one month after his retirementnews2022-05-02T14:53:40+00:00May 2nd, 2022|Fierce Pharma|
Bayer investors reject management compensation for 2021 but back company’s overall performancenews2022-05-02T14:48:00+00:00May 2nd, 2022|Fierce Pharma|
FDA snubs another China-made cancer drug, foiling Hutchmed’s first shot at US marketnews2022-05-02T14:13:21+00:00May 2nd, 2022|Fierce Pharma|
Paxlovid’s post-exposure protection flop hardly spells the end for Pfizer’s COVID franchise: analystsnews2022-05-02T13:13:49+00:00May 2nd, 2022|Fierce Pharma|
Orphalan pushes first drug for Wilson’s disease in 5 decades over FDA finish linenews2022-05-02T11:57:39+00:00May 2nd, 2022|Fierce Pharma|
After a nasty quarter for AbbVie’s migraine franchise, Biohaven investors worry about pricingnews2022-05-02T10:38:47+00:00May 2nd, 2022|Fierce Pharma|
Klick Health brings on creative veteran Romero, formerly of The Bloc, for unique ‘Maker’ rolenews2022-04-30T00:58:43+00:00April 30th, 2022|Fierce Pharma|
AbbVie’s red-hot Rinvoq scores fourth FDA approval in five monthsnews2022-04-29T20:40:58+00:00April 29th, 2022|Fierce Pharma|
AbbVie’s red-hot Rinvoq scores 4th FDA approval in 5 monthsnews2022-04-29T20:40:58+00:00April 29th, 2022|Fierce Pharma|
